Abstract
Purpose
To evaluate the role of bevacizumab injected into the silicone oil at the end of retinal reattachment surgery for rhegmatogenous retinal detachment (RRD) associated with severe proliferative vitreoretinopathy (PVR) for prevention of postoperative PVR and compare the results with those without intrasilicone injection.
Methods
In this prospective comparative interventional study, eyes with RRD with grade C PVR were included. Standard 20 gauge pars plana vitrectomy, and retinal reattachment was performed. In case group, 1.25 mg bevacizumab was injected into the silicone oil at the end of surgery. The rate of retinal redetachment associated with PVR was assessed.
Results
In all 38 eyes of 38 patients (19 cases and 19 controls) with a mean age of 46.6±18.3 years were studied. The two groups were matched for age, sex, preoperative visual acuity, presence of anterior and posterior PVR, extent of PVR, and history of previous retinal detachment surgery. Retinal redetachment with PVR occurred in nine (47.3%) and seven (36.8%) eyes in case and control groups, respectively (P=0.5). Extensive subretinal fibrous proliferations in addition to preretinal membranes occurred more in the case group (55.5 vs 14.3%). At final visit, visual acuity was similar between the two groups (1.6±0.8 and 1.6±0.6, respectively, P=0.9).
Conclusion
Intrasilicone injection of bevacizumab at the end of vitrectomy for RRD with severe PVR does not eliminate the risk of postoperative PVR.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Haimann MH, Burton TC, Brown CK . Epidemiology of retinal detachment. Arch Ophthalmol 1982; 100: 289–292.
Wilkes SR, Beard CM, Kurland LT, Robertson DM, O’Fallon WM . The incidence of retinal detachment in Rochester, Minnesota, 1970-1978. Am J Ophthalmol 1982; 94: 670–673.
D’Amico DJ . Clinical practice. Primary retinal detachment. N Engl J Med 2008; 359: 2346–2354.
Pastor JC . Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 1998; 43: 3–18.
Pastor JC, de la Rúa ER, Martín F . Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 2002; 21: 127–144.
Fredj-Reygrobellet D, Baudouin C, Nègre F, Caruelle JP, Gastaud P, Lapalus P . Acidic FGF and other growth factors in preretinal membranes from patients with diabetic retinopathy and proliferative vitreoretinopathy. Ophthalmic Res 1991; 23: 154–161.
Chen YS, Hackett SF, Schoenfeld CL, Vinores MA, Vinores SA, Campochiaro PA . Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthalmol 1997; 81: 919–926.
Spraul CW, Kaven C, Lang GK, Lang GE . Effect of growth factors on bovine retinal pigment epithelial cell migration and proliferation. Ophthalmic Res 2004; 36: 166–171.
Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M . Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Am J Ophthalmol 2002; 133: 851–852.
Su CY, Chen MT, Wu WS, Wu WC . Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. J Ocul Pharmacol Ther 2000; 16: 463–469.
Citirik M, Kabatas EU, Batman C, Akin KO, Kabatas N . Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy. Ophthalmic Res 2012; 47 (1): 7–12.
Ricker LJAG, Dieudonne SC, Kessels AGH, Rennel ES, Berendschot TT, Hendrikse F et al. Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinoapthy. Retina 2011; 32 (1): 54–59.
Rasier R, Gormus U, Artunay O . Vitreous levels of VEGF, IL-8, and TNF-α in retinal detachment. Current Eye Res 2010; 35: 505–509.
Ferrara N, Hillan KJ, Gerber HP, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3 (5): 391–400.
Grisanti S, Ziemssen F . Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol 2007; 55 (6): 417–420.
Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113 (3): 363–372.
Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM . Intravitreal injection of 2.5mg versus 1.25mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009; 29 (3): 319–324.
Oshima Y, Sakaguchi H, Gomi F, Tano Y . Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142 (1): 155–158.
Falavarjani KG, Modarres M . Perioperative use of bevacizumab in vitrectomy for proliferative diabetic retinopathy: a literature review. Iranian J Ophthalmol 2010; 22 (4): 5–12.
Falavarjani KG, Modarres M, Nazari H . Therapeutic effect of Bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye 2010; 24: 717–719.
Nazari H, Parvaresh MM, Modarres M, Falavarjani KG . Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1713–1718.
Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM . An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 1991; 112: 159–165.
Charteris DG, Sethi CS, Lewis GP, Fisher SK . Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye 2002; 16: 369–374.
Wickham L, Bunce C, Wong D, McGurn D, Charteris DG . Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 2007; 114: 698–704.
Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR . Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology 2008; 115: 1938–1943.
Kiss C, Michels S, Prager F, Weigert G, Geitzenauer W, Schmidt-Erfurth U . Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006; 26: 877–881.
Mehdizadeh M, Fattahi F, Eghtedari M, Nowroozzadeh MH, Toosi F . The role of intravitreal bevacizumab in experimental posterior penetrating eye injury. Retina 2011; 31 (1): 154–160.
Asaria RHY, Gregor ZJ . Simple retinal detachments: identifying the at-risk case. Eye 2002; 16: 404–410.
The Silicone Study Group. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Arch Ophthalmol 1992; 110: 780–792.
Ricker LJAG, Kijlstra A, Kessels AGH, de Jager W, Liem AT, Hendrikse F, La Heij EC . Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study. PLoS One 2011; 6 (4): e19141.
Hwang JC, Del Priore LV, Freund KB, Chang S, Iranmanesh R . Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2011; 42 (1): 6–11.
Batman C, Ozdamar Y . The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation. Ophthalmic Surg Lasers Imaging 2010; 41 (2): 190–195.
Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJ . A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 2012; 96 (4): 587–590.
Xu Y, You Y, Du W, Zhao C, Li J, Mao J et al. Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade. Invest Ophthalmol Vis Sci 2012; 53: 5221–5226.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ghasemi Falavarjani, K., Hashemi, M., Modarres, M. et al. Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye 28, 576–580 (2014). https://doi.org/10.1038/eye.2014.21
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2014.21
Keywords
This article is cited by
-
Proliferative vitreoretinopathy: an update on the current and emerging treatment options
Graefe's Archive for Clinical and Experimental Ophthalmology (2023)
-
Comment on ‘Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy’
Eye (2014)
-
Proliferative vitreoretinopathy and antivascular endothelial growth factor treatment
Eye (2014)
